ALISO VIEJO, Calif., Feb. 3, 2015 (GLOBE NEWSWIRE) -- CNS Response, Inc. (OTCQB:CNSO) applauds the 114th Congress for passing the Clay Hunt Suicide Prevention for American Veterans Act today. On average one active service member and 22 veterans are said to be taking their own lives each day. The independent oversight and evidence-based medicine called for in this bill could not come soon enough—especially for the families and loved ones of those veterans who did not receive the help they needed or deserved.
CNS Response is proud to have supported the Clay Hunt SAV Act with testimony submitted to Congress and thanks the many veterans and mental health advocacy groups, including Iraq and Afghanistan Veterans of America, Veterans of Foreign Wars, the American Psychiatric Association, and family members like Susan Selke who made today's passage possible.
Every day, CNS Response connects mental health patients and their doctors with medication options that work based on our proprietary database of real-world patient outcomes. Trial-and-error prescribing is not an adequate solution for those in pain. CNS Response gives patients and families the peace of mind that evidence-based, clinically proven technology delivers. CNS Response will continue to advocate for the improvements evidence-based care can deliver until everyone has access to quality mental health care.
Read CNS Response's Congressional Testimony here:
About CNS Response Inc.
CNS Response (www.cnsresponse.com) provides a unique set of reference data and analytic tools for clinicians and researchers in psychiatry. While treatment for mental disorders has doubled in the last 20 years, it is estimated that 17 million Americans have failed two or more medication therapies for their mental disorders. The Company's Psychiatric EEG Evaluation Registry, or PEER Online, is a new registry and reporting platform that allows medical professionals to exchange treatment outcome data for patients referenced to objective neurophysiology data obtained through a standard electroencephalogram (EEG). Based on the company's original physician-developed database, there are now more than 37,350 outcomes for over 9,900 unique patients in the PEER registry. The objective of PEER Online is to avoid trial and error pharmacotherapy, which is the dominant approach for treatment resistant patients.
To read more about the benefits of this patented technology for patients, physicians and payers, please visit www.cnsresponse.com. Medical professionals interested in learning more can contact CNS Response representatives at PEERinfo@cnsresponse.com.
Safe Harbor Statement Under the Private Securities Litigation Reform Act of 1995
Except for the historical information contained herein, the matters discussed are forward-looking statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, as amended. These forward-looking statements involve risks and uncertainties as set forth in the Company's filings with the Securities and Exchange Commission. These risks and uncertainties could cause actual results to differ materially from any forward-looking statements made herein.